Pressure intensifies on Novartis as bolt-on deal strategy faces major test
Novartis is facing scrutiny towards its merger and acquisition (M&A) strategy after trial setbacks have rocked investors’ confidence in its…
Novartis is facing scrutiny towards its merger and acquisition (M&A) strategy after trial setbacks have rocked investors’ confidence in its…
The US Food and Drug Administration (FDA) has proposed a new rule that will simplify the registration step for certain…
Biopharma executives’ confidence in the industry has reached its highest point in four years, reflecting a successful navigation through a…
The Cystic Fibrosis Foundation will supply up to $13m of funding to SpliSense, helping the biotech continue development of its…
With the leadership role of the US Food and Drug Administration (FDA) vacant following Marty Makary’s resignation earlier this week,…
Faced with growing competition in the global clinical trials landscape, many countries are reforming regulatory frameworks in a bid to…
Clinical trial reforms have become abundant across the global pharmaceutical industry as regions look to stake their claim in attracting…
It’s been a busy year for rare disease developers, with the US Food and Drug Administration (FDA) releasing several new…
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway”, a new…
The US is poised to leave the World Health Organization (WHO) as the one-year countdown of legal notice comes to…